Cerebroprotective potential of ceftriaxone against cadmium chloride-induced cerebral inflammatory changes and oxidative insult.
📄 Abstract
Cadmium (Cd) is a potent neurotoxic heavy metal associated with cerebral oxidative disturbances. The beta-lactam antibiotic ceftriaxone has been known to modulate the expression of GLT-1, the primary glutamate transporter. This research has been framed to evaluate the potential neurodefensive activity of ceftriaxone against cadmium chloride (CdCl
Confidence:
0.08
· 4 полей извлечено
Идентификация (6 полей)
Target
—
0.00
Alt. target
—
0.00
Protein family
—
0.00
Functional class
—
0.00
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Ceftriaxone evaluated for neuroprotection against cadmium chloride-induced cerebral damage in rats; resveratrol studied in lead and cadmium co-exposed rats; prenatal cadmium exposure effects on male infertility in mice; cadmium-induced liver dysfunction in mice; desert milk exosomes in LPS-induced cognitive decline model.
0.90
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
Rats, mice
0.90
Diet/model
Cadmium chloride exposure, lead and cadmium co-exposure, LPS-induced cognitive decline
0.90
Клиника (11 полей)
Drug
ceftriaxone
0.95
Indication
—
0.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00